BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33581325)

  • 21. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
    Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
    Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas.
    Al-Harthy M; Al-Harthy S; Al-Otieschan A; Velagapudi S; Alzahrani AS
    Endocr Pract; 2009 Apr; 15(3):194-202. PubMed ID: 19364686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma.
    Karakaya S; Gunnesson L; Elias E; Martos-Salvo P; Robledo M; Nilsson O; Wängberg B; Abel F; Påhlman S; Muth A; Mohlin S
    Sci Rep; 2023 Jul; 13(1):11588. PubMed ID: 37463949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
    Mete O; Pakbaz S; Lerario AM; Giordano TJ; Asa SL
    Am J Surg Pathol; 2021 Sep; 45(9):1264-1273. PubMed ID: 33826547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
    Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pheochromocytomas and Hypertension.
    Pappachan JM; Tun NN; Arunagirinathan G; Sodi R; Hanna FWF
    Curr Hypertens Rep; 2018 Jan; 20(1):3. PubMed ID: 29356966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
    Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
    Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma.
    Miyauchi M; Akashi T; Furukawa A; Uchida K; Tamura T; Ando N; Kirimura S; Shintaku H; Yamamoto K; Ito T; Miura K; Kayamori K; Ariizumi Y; Asakage T; Kudo A; Tanabe M; Fujii Y; Ishibashi H; Okubo K; Murakami M; Yamada T; Takemoto A; Bae Y; Eishi Y; Ohashi K
    Endocr Pathol; 2022 Dec; 33(4):506-518. PubMed ID: 36029394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pheochromocytomas and paragangliomas.
    Yen K; Lodish M
    Curr Opin Pediatr; 2021 Aug; 33(4):430-435. PubMed ID: 34039901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management.
    Jain A; Baracco R; Kapur G
    Pediatr Nephrol; 2020 Apr; 35(4):581-594. PubMed ID: 30603807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical differences between small and large pheochromocytomas and paragangliomas.
    Zhao L; Li Z; Meng X; Fan H; Zhang Z; Zhang Z; Liu Y; Zhou X; Zhu H
    Front Endocrinol (Lausanne); 2023; 14():1087506. PubMed ID: 36967797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy.
    Liu L; Xie W; Song Z; Wang T; Li X; Gao Y; Li Y; Zhang J; Guo X
    Clin Endocrinol (Oxf); 2022 Feb; 96(2):132-138. PubMed ID: 34486152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High specificity of spot urinary free metanephrines in diagnosis and prognosis of pheochromocytomas and paragangliomas by HPLC with electrochemical detection.
    Zuo M; Zhen Q; Zhang X; Zou W; Yang X; Tian G; Shi Z; Li Q; Ding M
    Clin Chim Acta; 2018 Mar; 478():82-89. PubMed ID: 29273559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
    Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas.
    Patel HV; Srivastava A; Becker MD; Beninato T; Laird AM; Singer EA
    Curr Urol Rep; 2021 Jan; 22(1):2. PubMed ID: 33403502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity.
    Vit O; Patel M; Musil Z; Hartmann I; Frysak Z; Miettinen M; Pacak K; Petrak J
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetics and imaging of pheochromocytomas and paragangliomas: current update.
    Katabathina VS; Rajebi H; Chen M; Restrepo CS; Salman U; Vikram R; Menias CO; Prasad SR
    Abdom Radiol (NY); 2020 Apr; 45(4):928-944. PubMed ID: 31069476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion.
    Geroula A; Deutschbein T; Langton K; Masjkur J; Pamporaki C; Peitzsch M; Fliedner S; Timmers HJLM; Bornstein SR; Beuschlein F; Stell A; Januszewicz A; Prejbisz A; Fassnacht M; Lenders JWM; Eisenhofer G
    Eur J Endocrinol; 2019 Oct; 181(4):409-420. PubMed ID: 31370000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force.
    Ku EJ; Kim KJ; Kim JH; Kim MK; Ahn CH; Lee KA; Lee SH; Lee YB; Park KH; Choi YM; Hong N; Hong AR; Kang SW; Park BK; Seong MW; Kim M; Jung KC; Jung CK; Cho YS; Paeng JC; Kim JH; Ryu OH; Rhee Y; Kim CH; Lee EJ
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):322-338. PubMed ID: 33820394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic IDH1 Hotspot Variants in Chinese Patients With Pheochromocytomas and Paragangliomas.
    Li M; He Y; Pang Y; Zhang J; Feng Y; He Y; Xu X; Wei Y; Zhong D; Deng W; Wang L; Yan B; Jiang Y; Xu N; Cai H; Wen Y; Ning J; Liu Y; Gao X; Shan Z; Liu L; Teng X; Richter S; Jiang J
    J Clin Endocrinol Metab; 2023 Apr; 108(5):1215-1223. PubMed ID: 36355572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.